Home > Search Results: Bakker, Nicolaas A.
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 2 records in 0.03 seconds.
Articles, 2 records found
Articles 2 records found  
1.
10 p, 306.4 KB Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone : analyses from the Phase II HORIZON study / Larocca, Alessandra (Azienda Ospedaliero - Universitaria Città della Salute e della Scienza) ; Leleu, Xavier (CHU de Poitiers) ; Touzeau, Cyrille (Université d'Angers) ; Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Paner, Agne (Rush University Medical Center) ; Mateos, M. V (Instituto de Investigación Biomédica de Salamanca) ; Cavo, Michele (Bologna University School of Medicine) ; Maisel, Christopher (Baylor Scott & White Charles A) ; Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Raptis, Anastasios (niversity of Pittsburgh School of Medicine) ; Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ; Mazumder, Amitabha (The Oncology Institute of Hope and Innovation) ; Laubach, Jacob (Harvard Medical School) ; Nadeem, Omar (Harvard Medical School) ; Sandberg, Anna (Oncopeptides AB (Suècia)) ; Orre, Marie (Oncopeptides AB (Suècia)) ; Torrång, Anna (SDS Life Science (Suècia)) ; Bakker, Nicolaas A (Oncopeptides AB) ; Richardson, Paul G.. (Harvard Medical School) ; Universitat Autònoma de Barcelona
Relapsed/refractory multiple myeloma (RRMM) is known to have a high burden of disease and complications associated with refractoriness to prior lines of therapy. Severe pain and fatigue symptoms and impairments in physical and emotional functioning have been strongly linked to reduced health-related quality of life (HRQoL) in patients with RRMM. [...]
2022 - 10.1111/bjh.17887
British Journal of Haematology, Vol. 196 Núm. 3 (february 2022) , p. 639-648  
Detailed record - Creative Commons
2.
13 p, 449.0 KB Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma / Richardson, Paul G.. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Larocca, Alessandra (Università di Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza) ; Bladé Creixenti, Juan (Hospital Clínic i Provincial de Barcelona) ; Cavo, Michele (Seràgnoli Institute of Hematology. Bologna University School of Medicine) ; Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ; Leleu, Xavier (CHU de Poitiers) ; Nadeem, Omar (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ; Hiemenz, John W. (Division of Hematology-Oncology. Department of Medicine. University of Florida) ; Hassoun, Hani (Memorial Sloan Kettering Cancer Center) ; Touzeau, Cyrille (Université de Nantes) ; Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ; Paner, Agne (Rush University Medical Center) ; Maisel, Christopher (Baylor Scott & White Charles A. Sammons Cancer Center) ; Mazumder, Amitabha (Oncology Institute of Hope and Innovation) ; Raptis, Anastasios (Universityof Pittsburgh School of Medicine) ; Moreb, Jan S. (Novant Health Hematology. Novant Health Forsyth Medical Center) ; Anderson, Kenneth C. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ; Laubach, Jacob P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ; Thuresson, Sara (Oncopeptides AB) ; Thuresson, Marcus (Oncopeptides AB) ; Byrne, Catriona (Oncopeptides AB) ; Harmenberg, Johan (Oncopeptides AB) ; Bakker, Nicolaas A. (Oncopeptides AB) ; Mateos, M. V (Hospital Clínico Universitario (Salamanca))
PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma (RRMM), a population with an important unmet medical need. [...]
2021 - 10.1200/JCO.20.02259
Journal of Clinical Oncology, Vol. 39 Núm. 7 (january 2021) , p. 757-767  
Detailed record - Creative Commons

See also: similar author names
1 Bakker, N.A.
1 Bakker, Nicolaas A
1 Bakker, Noëlle
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with